007足球比分即时网

Bio-Thera Solutions’ Golimumab Biosimilars Receive FDA Approval as First Biosimilars to Simponi® and Simponi Aria®; Accord BioPharma to Commercialize IMMGOLIS™ (golimumab-sldi) and IMMGOLIS INTRI™ (golimumab-sldi) in the United States

2026-05-18

GUANGZHOU, China --- Bio-Thera Solutions (688177:SH), a commercial-stage biopharmaceutical company developing a pipeline...

查看详情

09-282021

Bio-Thera Solutions and Intract Pharma Enter Global Collaboration and License Agreement for Soteria® and Phloral® Drug Delivery Technologies to Enable Development of Oral Antibody Medicines

GUANGZHOU, China, September 27,2021 (BUSINESSWIRE) –Bio-Thera Solutions, Ltd. (688177.SH, “Bio-Thera”)and Intract Pharma...
09-082021

Bio-Thera Solutions Announces Commercialization and License Agreement for BAT1706, a Proposed Biosimilar Referencing Avastin® (Bevacizumab)

®Under the agreement, Bio-Thera will maintain responsibilities for development, manufacturing, and supply of BAT1706. Sa...
08-272021

Bio-Thera Solutions and Hikma Pharmaceuticals announce exclusive commercialization and license agreement for BAT2206 in the US, a proposed biosimilar referencing Stelara® (ustekinumab)

Guangzhou and London, 27 August2021–Bio-Thera Solutions, Ltd. (688177.SH) and Hikma Pharmaceuticals PLC (LSE: HIK) today...

上一页 ···22 23 24 25 26 ··· 下一页